Welcome!

News Feed Item

Response Biomedical Corp. Announces Second Quarter 2014 Financial Results

VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 08/11/14 -- Response Biomedical Corp. ("Response" or "the Company") (TSX:RBM)(OTCBB:RPBIF) today reported financial results for the second quarter and six months ended June 30, 2014 including a 12% increase in sales and improving gross margin.

Response's Chief Executive Officer, Jeff Purvin, commented on Response's Q2 2014 performance saying, "I am happy to report that our new China distributors are continuing to place new orders this quarter. Total sales in China were approximately $350 thousand more in this quarter than last quarter, indicating that these distributors are starting to work through their initial stocking inventories and are developing new demand in the marketplace."

Mr. Purvin added, "Sales in the US were relatively unchanged from the previous year with the exception of Biodefense and West Nile Virus testing sales which increased by 30%, primarily due to the successful sales efforts of our distributors and the timing of orders. US cardiac sales have been slower than we expected and we are in the process of refocusing our resources on the specific hospital groups and other opportunities that will benefit the most from our products. We will be reallocating some of our current US spending over to China, where it will likely have a more immediate impact on our sales growth, this year and next. Sales in the rest of the world, excluding China and the US, increased 22% versus last year to $674 thousand in the quarter as we continue to strengthen our overseas distribution networks. This growth was hampered by lower quarter over quarter sales to our Russian distributor due to factors resulting from the recent unrest in that country. Russia is our second biggest market after China.

"Importantly, we were able to improve our gross margin percentage during the quarter to 44.6%. The efficiencies we've achieved in manufacturing and purchasing over the past year, along with positive exchange fluctuations, have contributed to the improvement in margin. We anticipate that these efficiencies will continue to benefit the company in the future as our unit sales volumes increase. All of the changes we are making now will require time to take full effect. However, because of the quality and quantity of the changes we've made, I feel confident that this plan will allow Response Biomedical to accelerate revenue growth and speed our progress toward profitability," concluded Mr. Purvin.

Financial results for the three months ended June 30, 2014


--  Product sales increased 12% to $3.08 million for the quarter ended June
    30, 2014 compared to $2.75 million for the same quarter in the previous
    year ended June 30, 2013: 
    
    --  Cardiovascular sales increased 9%, or $0.22 million, primarily due
        to increased sales in China as a result of the transition to new
        distribution partners; and 
        
    --  Infectious Disease, West Nile Virus and Biodefense sales increased
        30%, or $0.11 million compared to 2013, primarily due to the
        successful sales efforts of our distributors and the timing of
        orders. 
        
--  Gross margin increased to 44.6% for the quarter ended June 30, 2014,
    compared to a gross margin of 41.6% in the same quarter of 2013. This
    increase is primarily due to the numerous manufacturing efficiencies
    implemented along with reduced component material costs through price
    and volume negotiations and by purchasing from more economical
    suppliers. In addition, there was a decrease in inventory provisions
    along with a positive impact on our gross margin by an appreciated U.S.
    dollar. 
    
--  Operating expenses decreased by 12% to $1.88 million for the quarter
    ended June 30, 2014 compared to $2.13 million in the same quarter of
    2013. This decrease is primarily due to decreases in legal and stock
    based compensation expenses offset by increased spending in research and
    development for clinical and regulatory work in 2014.  
    
--  As a result of the changes described above, Adjusted EBITDA for the
    quarter ended June 30, 2014 improved to negative $0.23 million compared
    to negative $0.56 million in the same quarter of 2013. Adjusted EBITDA
    excludes, for the applicable periods, interest expense, interest income,
    income tax, depreciation and amortization, stock-based compensation
    expense, and the non-cash unrealized gain or loss on the revaluation of
    the warrant liability. We believe that this non-GAAP measure may be
    useful to investors to analyze the results of our business as we use
    this non-GAAP measure internally to evaluate our financial results. A
    reconciliation between net income (loss) and comprehensive income (loss)
    and Adjusted EBITDA is included below. 
    
--  GAAP Net income for the quarter ended June 30, 2014 totaled $0.29
    million, or $0.04 per basic and diluted share, compared to $3.34 million
    GAAP Net income, or $0.51 per basic share and a loss of $0.14 per
    diluted share, in the comparative 2013 period. The decrease in GAAP Net
    income was primarily due to a $3.43 million decrease in the unrealized
    gain on revaluation of the warrant liability offset by the increase in
    product sales and decrease in operating expenses mentioned above. 
    
--  Adjusted Net loss decreased by $0.38 million to $0.75 million from $1.13
    million in the comparable quarter in 2013. We also believe that this
    non-GAAP measure, along with Adjusted EBITDA, may be useful to investors
    to analyze the results of our business because it excludes the often
    volatile, non-cash unrealized change in the valuation of the Company's
    warrant liability. A reconciliation between Net income (loss) and
    comprehensive income (loss) and Adjusted Net loss is included below.  

Financial results for the six months ended June 30, 2014


--  Product sales decreased 11% to $5.64 million for the six month period
    ended June 30, 2014 compared to $6.31 million for the comparative period
    ended June 30, 2013: 
    
    --  Cardiovascular sales decreased 4%, or $0.19 million, primarily due
        to reduced sales in China in the first quarter as a result of the
        transition to new distribution partners which began in the fourth
        quarter of 2013; and 
        
    --  Infectious Disease, West Nile Virus and Biodefense sales have
        decreased 45%, or $0.48 million compared to 2013, primarily due to
        the seasonal increase in demand for Influenza sales in the first
        quarter of 2013 and the timing of orders by distributors. 
        
--  Gross margin increased to 44.2% for the six months ended June 30, 2014,
    compared to a gross margin of 43.4% in the same period of 2013. This
    increase is primarily due to numerous manufacturing efficiencies along
    with reduced component material costs by improved purchasing offsetting
    the impact of a decrease in our non-cardiovascular sales, which are sold
    at higher margins, described above. 
    
--  Operating expenses increased by 4% to $4.15 million for the six months
    ended June 30, 2014 compared to $3.99 million in the same period in
    2013. The increase is primarily due to increased spending in research
    and development for clinical and regulatory work in 2014 and an increase
    in sales and marketing expenses primarily related to expanded staffing
    offset by decreased general and administrative costs.  
    
--  As a result of the changes described above, Adjusted EBITDA for the six
    months ended June 30, 2014 was negative $1.03 million compared to
    negative $0.41 million in the same period of 2013 as a result of the
    decrease in product sales and increase in operating expenses described
    above. 
    
--  GAAP Net loss for the six months ended June 30, 2014 totaled $1.03
    million, or $0.16 per basic and diluted share, compared to a $6.62
    million GAAP Net loss, or $1.01 per basic and diluted share, in the
    comparative 2013 period. The decrease in the loss was primarily due to a
    $5.98 million decrease in the unrealized loss on revaluation of the
    warrant liability offset by the decrease in product sales and increase
    in operating expenses mentioned above. 
    
--  Adjusted Net loss for the six months ended June 30, 2014 increased by
    $0.59 million to $2.11 million from $1.52 million in the comparable
    period in 2013. 
    
--  Cash and cash equivalents as of June 30, 2014 were $2.61 million
    compared to $2.96 million as of December 31, 2013. During the six month
    period, the Company received US $1.5 million of the total US $2.5
    million term loan from Silicon Valley Bank that it had secured during
    the first quarter of 2014.  

For a further discussion of the Company's financial results for the second quarter ended June 30, 2014, please refer to the Company's consolidated financial statements and related Management Discussion and Analysis, which can be found at www.responsebio.com, SEDAR (Canada) www.sedar.com or EDGAR (U.S.) www.sec.gov/edgar/searchedgar/webusers.htm. Information at these sites is typically available within 24 hours of the distribution of the news release.

Non-GAAP Financial Measures

Management has presented its operating results in accordance with United States Generally Accepted Accounting Principles (GAAP) and on an "adjusted" (or non-GAAP) basis for the three and six months ended June 30, 2014 and 2013. We believe that the presentation of non-GAAP financial measures provides useful supplementary information to and facilitates additional analysis by investors. These non-GAAP financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in conformity with GAAP. Further, our reconciliation of GAAP Net income (loss) and comprehensive income (loss) to Adjusted EBITDA and Adjusted Net loss are included in the tables below to facilitate a reader's understanding of the impact of these adjustments to our GAAP financial results and are not intended to place any undue prominence on our Adjusted EBITDA and/or our Adjusted Net loss.

About Response Biomedical Corp.

Response develops, manufactures and markets rapid on-site diagnostic tests for use with its RAMP® Platform for clinical, biodefense and environmental applications. RAMP® represents a unique paradigm in diagnostics that provides reliable, quality results in minutes. The RAMP® Platform consists of a reader and single-use disposable test cartridges and has the potential to be adapted to any other medical and non-medical immunoassay based test currently performed in laboratories. Response clinical tests are commercially available for the aid in early detection of heart attack, congestive heart failure, influenza A and B and RSV. In the non-clinical market, RAMP® tests are currently available for the environmental detection of West Nile Virus and for Biodefense applications including the rapid on-site detection of anthrax, smallpox, ricin and botulinum toxin.

Response is a publicly traded company listed on the TSX under the trading symbol "RBM" and quoted on the OTC Bulletin Board under the symbol "RPBIF". For further information, please visit the Company's website at www.responsebio.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about Response Biomedical Corp. Examples of forward-looking statements in this press release include statements regarding our belief that our new distributors in China are starting to work through their initial stocking inventories and are developing new demand in the marketplace, our belief that reallocating some of our current US spending over to China will likely have a more immediate impact on our sales growth, this year and next, our belief that the efficiencies we have achieved in manufacturing and purchasing over the past year will benefit the Company in the future as our unit sales volumes increase, our expectation that all of the changes we are making now will require time to take full effect and our belief that the quality and quantity of the changes we've made will allow us to accelerate revenue growth and speed our progress toward profitability. These statements are only predictions based on our current expectations and projections about future events. Although we believe the expectations reflected in such forward-looking statements, and the assumptions upon which such forward-looking statements are made, are reasonable, there can be no assurance that such expectations will prove to be correct and if such expectations are not met, our business may suffer.

Readers should not place undue reliance on these statements. Actual events or results may differ materially. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many factors may cause the Company's actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual report on Form 10-K, our quarterly reports on Form 10-Q, our Current Reports on Form 8-K, our Annual Information Form and other filings with the Securities and Exchange Commission and Canadian securities regulatory authorities.

The forward-looking statements contained in this news release are current as of the date hereof and are qualified in their entirety by this cautionary statement. Except as expressly required by applicable securities laws, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Selected Financial Data (in thousands of Canadian dollars except per share data):


                               Three Months Ended       Six Months Ended    
                                    June 30                 June 30         
                                   2014        2013        2014        2013 
----------------------------------------------------------------------------
Product sales                 $   3,077   $   2,748   $   5,636   $   6,309 
Cost of sales                     1,705       1,606       3,145       3,571 
                            ------------------------------------------------
Gross profit on product                                                     
 sales                        $   1,372   $   1,142   $   2,491   $   2,738 
Gross margin on product                                                     
 sales                             44.6%       41.6%       44.2%       43.4%
Operating expenses                1,882       2,130       4,150       3,993 
Other expenses (excluding                                                   
 unrealized loss (gain) on                                                  
 revaluation of warrant                                                     
 liability)                         241         139         454         261 
                            ------------------------------------------------
Adjusted net loss             $    (751)  $  (1,127)  $  (2,113)  $  (1,516)
                            ------------------------------------------------
Unrealized loss (gain) on                                                   
 revaluation of warrant                                                     
 liability                       (1,039)     (4,470)       (878)      5,105 
                            ------------------------------------------------
Net income (loss) and                                                       
 comprehensive income (loss)                                                
 for the period               $     288   $   3,343   $  (1,235)  $  (6,621)
                            ------------------------------------------------
                            ------------------------------------------------
Income (loss) per share -                                                   
 basic                        $    0.04   $    0.51   $   (0.16)  $   (1.01)
Income (loss) per share -                                                   
 diluted                      $    0.04   $   (0.14)  $   (0.16)  $   (1.01)

Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (in thousands of Canadian dollars):


                               Three Months Ended       Six Months Ended    
                                    June 30                 June 30         
                                   2014        2013        2014        2013 
----------------------------------------------------------------------------
Adjusted EBITDA               $    (227)  $    (563)  $  (1,029)  $    (412)
Interest expense and                                                        
 amortization of deferred                                                   
 financing costs and debt                                                   
 discount                           226         175         423         351 
Interest income                      (4)         (4)         (9)         (7)
Income tax expense                   15          14          32          14 
Depreciation and                                                            
 amortization                       205         198         405         430 
Stock-based compensation             82         181         233         316 
Unrealized loss (gain) on                                                   
 revaluation of warrant                                                     
 liability                       (1,039)     (4,470)       (878)      5,105 
                            ------------------------------------------------
Net income (loss) and                                                       
 comprehensive income (loss)                                                
 for the period               $     288   $   3,343   $  (1,235)  $  (6,621)
                            ------------------------------------------------
                            ------------------------------------------------

Reconciliation of Adjusted Net Loss to GAAP Net Income (Loss) (in thousands of Canadian dollars):


                               Three Months Ended       Six Months Ended    
                                    June 30                 June 30         
                                   2014        2013        2014        2013 
----------------------------------------------------------------------------
Adjusted net loss             $    (751)  $  (1,127)  $  (2,113)  $  (1,516)
Unrealized loss (gain) on                                                   
 revaluation of warrant                                                     
 liability                       (1,039)     (4,470)       (878)      5,105 
                            ------------------------------------------------
Net income (loss) and                                                       
 comprehensive income (loss)                                                
 for the period               $     288   $   3,343   $  (1,235)  $  (6,621)
                            ------------------------------------------------
                            ------------------------------------------------

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Everyone wants to use containers, but monitoring containers is hard. New ephemeral architecture introduces new challenges in how monitoring tools need to monitor and visualize containers, so your team can make sense of everything. In his session at @DevOpsSummit, David Gildeh, co-founder and CEO of Outlyer, will go through the challenges and show there is light at the end of the tunnel if you use the right tools and understand what you need to be monitoring to successfully use containers in your...
Developers want to create better apps faster. Static clouds are giving way to scalable systems, with dynamic resource allocation and application monitoring. You won't hear that chant from users on any picket line, but helping developers to create better apps faster is the mission of Lee Atchison, principal cloud architect and advocate at New Relic Inc., based in San Francisco. His singular job is to understand and drive the industry in the areas of cloud architecture, microservices, scalability ...
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at Dell EMC, introduced a methodology for capturing, enriching and sharing data (and analytics) across the organization...
The explosion of new web/cloud/IoT-based applications and the data they generate are transforming our world right before our eyes. In this rush to adopt these new technologies, organizations are often ignoring fundamental questions concerning who owns the data and failing to ask for permission to conduct invasive surveillance of their customers. Organizations that are not transparent about how their systems gather data telemetry without offering shared data ownership risk product rejection, regu...
Grape Up is a software company, specialized in cloud native application development and professional services related to Cloud Foundry PaaS. With five expert teams that operate in various sectors of the market across the USA and Europe, we work with a variety of customers from emerging startups to Fortune 1000 companies.
Financial Technology has become a topic of intense interest throughout the cloud developer and enterprise IT communities. Accordingly, attendees at the upcoming 20th Cloud Expo at the Javits Center in New York, June 6-8, 2017, will find fresh new content in a new track called FinTech.
SYS-CON Events announced today that Interoute, owner-operator of one of Europe's largest networks and a global cloud services platform, has been named “Bronze Sponsor” of SYS-CON's 20th Cloud Expo, which will take place on June 6-8, 2017 at the Javits Center in New York, New York. Interoute is the owner-operator of one of Europe's largest networks and a global cloud services platform which encompasses 12 data centers, 14 virtual data centers and 31 colocation centers, with connections to 195 add...
@DevOpsSummit at Cloud taking place June 6-8, 2017, at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long developm...
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
The age of Digital Disruption is evolving into the next era – Digital Cohesion, an age in which applications securely self-assemble and deliver predictive services that continuously adapt to user behavior. Information from devices, sensors and applications around us will drive services seamlessly across mobile and fixed devices/infrastructure. This evolution is happening now in software defined services and secure networking. Four key drivers – Performance, Economics, Interoperability and Trust ...
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
Bert Loomis was a visionary. This general session will highlight how Bert Loomis and people like him inspire us to build great things with small inventions. In their general session at 19th Cloud Expo, Harold Hannon, Architect at IBM Bluemix, and Michael O'Neill, Strategic Business Development at Nvidia, discussed the accelerating pace of AI development and how IBM Cloud and NVIDIA are partnering to bring AI capabilities to "every day," on-demand. They also reviewed two "free infrastructure" pr...
Cloud Expo, Inc. has announced today that Aruna Ravichandran, vice president of DevOps Product and Solutions Marketing at CA Technologies, has been named co-conference chair of DevOps at Cloud Expo 2017. The @DevOpsSummit at Cloud Expo New York will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and @DevOpsSummit at Cloud Expo Silicon Valley will take place Oct. 31-Nov. 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA.
Most companies are adopting or evaluating container technology - Docker in particular - to speed up application deployment, drive down cost, ease management and make application delivery more flexible overall. As with most new architectures, this dream takes a lot of work to become a reality. Even when you do get your application componentized enough and packaged properly, there are still challenges for DevOps teams to making the shift to continuous delivery and achieving that reduction in cost ...
Translating agile methodology into real-world best practices within the modern software factory has driven widespread DevOps adoption, yet much work remains to expand workflows and tooling across the enterprise. As models evolve from pockets of experimentation into wholescale organizational reinvention, practitioners find themselves challenged to incorporate the culture and architecture necessary to support DevOps at scale. In his session at @DevOpsSummit at 20th Cloud Expo, Anand Akela, Senior...